查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1863190

人工智慧（AI）在癌症診斷的應用：全球洞察、競爭格局及市場預測（至2032年）

Artificial Intelligence (AI) in Cancer Diagnostics - Market Insights, Competitive Landscape, and Market Forecast - 2032
出版日期: | 出版商: DelveInsight | 英文 150 Pages | 商品交期: 2-10個工作天內

價格

人工智慧（AI）在癌症診斷領域的市場摘要

  • 全球癌症診斷領域人工智慧（AI）市場規模預計將強勁且永續成長，從 2024 年的 10.4918 億美元成長到 2032 年的 24.3432 億美元。
  • 全球癌症診斷人工智慧（AI）市場在 2025 年至 2032 年的預測期內將以 11.16% 的複合年成長率成長。
  • 隨著癌症發生率的上升，人們對早期精準檢測的需求日益成長，全球癌症診斷領域的人工智慧（AI）市場正迅速發展。人工智慧與電腦斷層掃描、MRI、乳房X光片和病理切片等醫學影像的融合日益緊密，提高了診斷準確率，減少了誤診，並實現了個人化治療。主要市場參與企業透過產品發布、合作和收購等策略性舉措，進一步提升了自身的技術能力和市場覆蓋範圍。這些因素正在加速人工智慧的應用，改善患者預後，並改變癌症診斷方式。
  • 癌症診斷人工智慧 (AI) 市場的主要企業包括 iCAD, Inc.、ibex-ai、羅氏診斷、Kheiron Medical Technologies Limited、MVision AI Inc.、西門子醫療、GE HealthCare、NVIDIA Corporation、Digital Diagnostics Inc.、IBM Corporation、Azra AI、ConcertAI、PathAI、Median Technologies、Paiger. Analytics。
  • 預計北美將繼續在人工智慧（AI）癌症診斷市場保持主導地位。這主要歸功於該地區較高的癌症發病率、對先進診斷解決方案日益成長的需求、政府的大力支持以及對人工智慧驅動型醫療技術的巨額投資。此外，眾多大型人工智慧開發商和知名醫學影像公司的存在也進一步推動了市場擴張。人工智慧與電子健康記錄（EHR）、精準醫療和數位病理學的融合，顯著提高了全部區域癌症檢測和診斷的效率、準確性和速度。
  • 在癌症診斷人工智慧 (AI) 市場的組件區隔領域中，預計到 2024 年，軟體類別將佔最大的市場佔有率。

推動人工智慧（AI）在癌症診斷市場成長的因素

  • 癌症發生率上升：全球癌症發生率的不斷上升是推動癌症診斷領域人工智慧（AI）市場發展的主要因素。隨著新增癌症病例數量的持續成長，醫療系統面臨著提供及時準確診斷的巨大壓力。這種迫切需求促使醫院和診斷中心部署基於人工智慧的解決方案，以期更早發現癌症、改善預後並輔助制定有效的治療方案。日益加重的疾病負擔直接推動了對先進診斷技術的需求，使人工智慧成為現代腫瘤治療的關鍵工具。
  • 增強醫學影像與人工智慧在癌症診斷中的融合：人工智慧與電腦斷層掃描、MRI、乳房X光檢查和病理切片等醫學顯像模式的融合，正在提升癌症診斷的準確性、效率和可靠性。人工智慧演算法能夠快速處理和分析大量複雜的影像數據，識別出人類放射科醫生可能遺漏的細微異常，從而減少假陽性和假陰性結果。這種能力不僅加快了診斷速度，還有助於制定個人化的治療方案，最終改善患者預後，並最佳化醫療機構的臨床工作流程。
  • 全球主要市場參與企業策略活動日益增多：主要市場參與企業透過產品發布、併購和合作等策略活動，在塑造人工智慧在癌症診斷市場中的地位方面發揮關鍵作用。這些舉措使企業能夠擴展其技術能力，開發創新的人工智慧驅動型診斷解決方案，並鞏固其在全球市場的地位。與研究機構、醫院和技術供應商的合作也加速了尖端人工智慧工具的商業化，促進了創新，並加強了人工智慧技術在全球腫瘤治療領域的應用。

人工智慧（AI）在癌症診斷市場的應用報告

本報告全面概​​述了全球市場，重點闡述了關鍵趨勢、成長要素、課題和機會。報告按組件、癌症類型、最終用戶和地區進行了詳細的市場區隔。報告深入分析了北美、歐洲和亞太地區等主要市場的競爭格局、法規環境和市場動態，並提供了寶貴的見解。報告詳細介紹了主要行業參與企業關鍵數據，以識別市場潛力、制定戰略計劃，並在快速成長的人工智慧（AI）癌症診斷市場中把握新的機會。

人工智慧（AI）在癌症診斷中的應用是指利用先進的計算演算法、機器學習和數據驅動模型來分析醫療數據，例如影像、實驗室結果和病患病歷，以輔助疾病的檢測、診斷和預後。透過識別人眼難以發現的模式和異常情況，人工智慧可以提高診斷準確率，加快決策速度，並支援個人化治療方案的製定，從而改善患者預後並提高臨床工作流程的效率。

人工智慧（AI）在癌症診斷領域的市場成長受到多種相互關聯的因素所驅動。全球癌症發生率的不斷攀升使得早期精準檢測成為當務之急，迫使醫療機構採用先進的AI診斷解決方案，以改善預後並輔助制定有效的治療方案。同時，AI與電腦斷層掃描、MRI、乳房X光攝影和病理切片等醫學顯像模式的日益融合，也提高了診斷的準確性和效率。

人工智慧演算法能夠快速分析大量複雜的影像數據，檢測出人類放射科醫生可能遺漏的細微異常，並減少假陽性和假陰性結果，從而加快診斷速度，並實現個人化治療策略。此外，主要市場參與企業的產品發布、併購和合作等策略性舉措進一步鞏固了市場地位。這些舉措正在拓展技術能力，激發創新，並擴大人工智慧驅動的癌症診斷解決方案的全球覆蓋範圍。

這些因素正在匯聚，推動人工智慧在腫瘤學領域的快速應用，改善患者預後，最佳化臨床工作流程，並改變全球癌症診斷格局。

受癌症發病率上升和對早期精準檢測需求不斷成長的推動，人工智慧在癌症診斷市場正經歷顯著成長。人工智慧與電腦斷層掃描、MRI、乳房X光檢查和病理切片等醫學影像技術的融合，提高了診斷準確率，最大限度地減少了誤診，並實現了個人化治療方案。主要市場參與企業透過產品發布、合作和收購等策略性舉措，進一步增強了自身的技術實力，並擴大了市場佔有率。這些因素共同推動了人工智慧的廣泛應用，改善了患者的治療效果，並正在改變全球癌症診斷領域的格局。

癌症仍然是市場成長的主要推動力。根據DelveInsight分析，預計2025年全球新增癌症病例將達2,150萬例，2045年將增加至3,250萬例。 2025年全球新增乳癌病例約250萬例，預計2045年將增加至335萬例。同時，預計2025年新增攝護腺癌病例為155萬例，至2050年將增加至285萬例。日益成長的全球癌症負擔推動了對先進診斷解決方案的需求，而人工智慧在提高早期檢測、診斷準確性和治療效果方面發揮關鍵作用。傳統的診斷方法，例如切片檢查和人工解讀影像，既耗時又容易出現人為錯誤。相較之下，人工智慧解決方案能夠自動檢測，分析來自各種影像模式的大量資料集，並整合基因組和患者數據，從而幫助腫瘤科醫師制定個人化的治療方案。

醫學影像與人工智慧的融合正在革新癌症診斷，顯著提升診斷的準確性、效率和早期發現率。借助深度學習演算法和電腦視覺技術，人工智慧驅動的影像解決方案能夠偵測到人類觀察者可能忽略的模式和異常情況。這些技術改進了影像分割、病灶檢測和腫瘤分類，從而實現更早、更準確的診斷。先進的人工智慧模型能夠以更高的靈敏度和特異性區分良性腫瘤和惡性腫瘤，減少假陽性結果和不必要的切片檢查。此外，人工智慧工具還有助於監測腫瘤進展、評估治療效果和預測疾病復發，使腫瘤科醫師能夠做出更明智的決策，從而實現個人化的患者照護。

主要市場參與企業的策略性舉措正在進一步加速市場成長。例如，2024年9月，羅氏透過其navify®數位病理企業軟體，整合了來自八家新合作夥伴的20多種先進人工智慧演算法，擴展了其數位病理平台。此舉將提升癌症研究和診斷能力，使病理學家能夠無縫存取尖端人工智慧技術，並加速人工智慧解決方案在臨床環境中的應用。

因此，癌症發病率的上升、技術的不斷創新以及積極的行業策略預計將在預測期內推動全球癌症診斷人工智慧市場顯著成長，從而改變腫瘤治療並提高全球診斷準確性。

然而，全球人工智慧（AI）市場在癌症診斷領域的成長面臨許多課題，尤其是在機器學習和腫瘤學領域。資料可用性有限且資料品質參差不齊是主要障礙，因為人工智慧系統需要大量高品質的資料集才能有效地訓練其演算法。不一致或不完整的醫學影像、基因組和臨床數據會降低模型準確性並降低診斷可靠性。此外，嚴格的監管和倫理問題進一步限制了市場擴張。人工智慧驅動的診斷工具必須經過廣泛的臨床檢驗，以證明其安全性、準確性和有效性，而跨多個地區應對複雜的法規結構可能會延遲核准和產品上市。包括病人知情同意、資料隱私和公平取得在內的倫理考量，也增加了實施的複雜性。

總體而言，數據品質和可用性的限制，加上嚴格的監管和倫理要求，限制了人工智慧在癌症診斷方面的潛力，即使該技術不斷改進早期檢測、提高工作流程效率並支持腫瘤學中的精準醫療舉措。

人工智慧（AI）在癌症診斷領域的市場

癌症診斷人工智慧 (AI) 市場區隔分析—按組件、癌症類型、最終用戶和地區分類

人工智慧（AI）在癌症診斷的應用

預計到2024年，以美國為首的北美地區將佔全球人工智慧（AI）癌症診斷市場51%的主導地位。北美地區在人工智慧（AI）癌症診斷市場的領先地位可歸因於該地區較高的癌症發病率、對先進診斷解決方案日益成長的需求、政府的大力支持以及對人工智慧驅動型醫療技術的巨額投資。此外，該地區眾多大型人工智慧開發商和知名醫學影像公司的存在也進一步推動了市場擴張。人工智慧與電子健康記錄（EHR）、精準醫療和數位病理學的融合，顯著提高了全部區域癌症檢測和診斷的效率、準確性和速度。

根據DelveInsight（2025）的預測，2025年北美將新增約290萬例癌症病例，預計2045年將增加至385萬例。乳癌是癌症整體負擔的主要組成部分，預計2025年新增病例約32.5萬例，2045年將增加至38.5萬例。人工智慧驅動的診斷解決方案在乳癌檢測中發揮關鍵作用，它能夠以極高的準確率分析乳房X光片、超音波和磁振造影（MRI）影像。這些技術不僅減少了假陽性和假陰性，還提高了診斷的可靠性。先進的機器學習演算法可以識別人類放射科醫生可能忽略的細微影像模式，從而實現更早、更準確的診斷。此外，人工智慧還可以將影像數據與基因組和臨床資訊整合，以輔助進行全面的風險評估、腫瘤分類和個人化治療方案的發展。

北美市場因主要產業參與企業的策略性舉措（併購、監管核准和新產品發布）而進一步鞏固。這些舉措加速了技術創新，拓展了產品系列，並增強了市場影響力，從而促進了創新人工智慧癌症檢測和治療解決方案的普及應用。例如，2023年10月，飛利浦與影像生物標記專家Quibim合作，推出了一款用於磁振造影（MR）前列腺篩檢的人工智慧影像和報告解決方案。此類合作對於提升診斷能力和滿足該地區日益成長的醫療需求至關重要。

因此，癌症發病率上升、技術不斷創新、法規結構支援以及積極的行業策略預計將在預測期內（即 2025-2032 年）推動北美癌症診斷人工智慧市場的發展。

由於完善的醫療保健體系、強大的研發實力以及鼓勵數位化醫療應用的政府政策，歐洲癌症診斷領域的人工智慧（AI）市場正穩步成長。德國、英國、法國和荷蘭等國在人工智慧診斷工具的應用方面處於主導，尤其是在影像學、病理學和預測分析領域，這些工具有助於提高癌症早期檢出率、提升診斷準確性並支持個人化治療策略。

醫院、學術機構和技術供應商之間的合作舉措正在促進創新，並加速人工智慧解決方案的商業化。包括歐盟醫療設備法規 (MDR) 和醫療保健領域人工智慧指南法規結構，透過確保人工智慧診斷系統的安全性、有效性和互通性，正在塑造市場動態。此外，雲端運算、巨量資料分析和遠端醫療解決方案的日益整合，使得人工智慧工具能夠在臨床環境中實現擴充性和高效部署。新興企業和中型企業正透過小眾人工智慧應用和創新平台積極推動市場成長，而現有企業則持續利用其豐富的數據資源和技術專長。

因此，歐洲市場的特點是創新、監管合規和技術成熟度之間的平衡互動，推動了人工智慧在癌症診斷領域的廣泛應用，並鞏固了歐洲在全球格局中作為主要參與企業的地位。

亞太地區癌症診斷人工智慧（AI）市場正經歷快速成長，這主要得益於癌症發病率的上升、醫療費用支出的增加以及全部區域先進數位技術的普及應用。中國、日本、印度和韓國等國家正崛起為人工智慧驅動型診斷解決方案的主要中心，這得益於這些國家對醫療基礎設施的大量投資、政府推動人工智慧融合的舉措，以及資料科學和醫學影像領域專業人才的不斷湧現。

人工智慧在診斷影像、病理學和基因組學領域的應用日益廣泛，旨在增強早期檢測能力、提高診斷準確性並實現個人化治療方案。醫院、研究機構和技術供應商之間的合作正在加速在地化人工智慧解決方案的開發和應用。同時，Start-Ups正專注於開發經濟高效且擴充性的平台，以滿足不同地區的醫療保健需求。法規結構也在不斷發展，以適應基於人工智慧的醫療技術，監管機構優先考慮臨床檢驗、資料隱私和互通性標準，以促進信任和應用。此外，雲端運算、遠端醫療和行動診斷工具的整合正在擴大人工智慧驅動的癌症診斷的覆蓋範圍，尤其是在農村和醫療資源匱乏的地區。

因此，亞太市場的特點是充滿活力的創新、不斷成長的公共和私營部門投資，以及對以患者為中心的在地化人工智慧解決方案的重視，這使得該地區成為全球癌症診斷人工智慧領域快速成長的貢獻者。

以下是引領癌症診斷人工智慧（AI）市場的主要企業，它們共同佔最大的市場佔有率，並主導產業趨勢：

  • iCAD, Inc.
  • ibex-ai
  • Roche Diagnostics
  • Kheiron Medical Technologies Limited
  • MVision AI Inc.
  • Siemens Healthineers AG
  • GE HealthCare
  • NVIDIA Corporation
  • Digital Diagnostics Inc.
  • IBM Corporation
  • Azra AI
  • ConcertAI
  • PathAI
  • Median Technologies
  • Paige AI Inc.
  • Therapixel
  • Flatiron
  • Freenome Holdings Inc.
  • Onc.AI
  • Sonrai Analytics

人工智慧（AI）在癌症診斷領域的市場格局相對集中，由少數主要企業和越來越多推動創新的新興新Start-Ups公司組成。 IBM Watson Health、Google Health、西門子醫療、GE醫療和飛利浦等老牌公司正憑藉其強大的研發能力、廣泛的資料生態系統以及與醫療機構的合作關係，不斷鞏固其市場地位。

這些公司正積極將人工智慧融入其現有的成像和診斷平台，擴展其以腫瘤學為中心的產品系列，並投資於預測分析和精準醫療解決方案；與此同時，新興企業和中型公司正透過專門的人工智慧演算法、雲端基礎的診斷平台和針對特定癌症類型的先進病理解決方案，為市場繁榮做出貢獻。

策略聯盟、併購和創業融資正成為關鍵的成長策略，使企業能夠增強技術實力並拓展地域版圖。此外，對互通性且符合監管要求的AI工具的需求日益成長，促使企業優先考慮獲得FDA批准、CE認證和開展臨床檢驗研究，以建立市場信譽。儘管市場由主要參與企業主導，但市場仍然對創新持開放態度，AI驅動的多模態診斷、即時影像解讀和生物標記發現等領域的進步為新進入者創造了機會。

因此，競爭格局體現了成熟的全球領導者和敏捷的創新者之間的平衡，兩者共同加速了人工智慧技術在癌症診斷中的應用，同時保持了適度集中的市場結構。

人工智慧（AI）在癌症診斷市場的最新發展趨勢

  • 2025年8月，Esaote宣布其MyLab™ A50和MyLab™ A70超音波診斷設備獲得FDA核准。這兩款攜帶式高性能成像平台先前已在國際市場銷售，如今獲准在美國上市，這標誌著Esaote在診斷成像領域創新方面邁出了重要一步。
  • 2025 年 8 月，FDA 授予 ArteraAI Prostate De Novo 批准，使其成為第一個能夠預測非轉移性前列腺癌長期結果的 AI 驅動軟體醫療設備。

人工智慧（AI）在癌症診斷領域的市場區隔

  • 人工智慧 (AI) 在癌症診斷中的應用趨勢（按組件分類）
  • 軟體
  • 服務
  • 人工智慧（AI）在癌症診斷的應用趨勢
  • 乳癌
  • 肺癌
  • 大腸直腸癌
  • 攝護腺癌
  • 腦和神經系統癌症
  • 其他
  • 人工智慧（AI）在癌症診斷中的應用趨勢（按終端用戶分類）
  • 醫院
  • 診斷中心
  • 其他
  • 人工智慧（AI）在癌症診斷中的區域趨勢
  • 北美癌症診斷人工智慧（AI）市場
  • 美國癌症診斷領域人工智慧（AI）市場
  • 加拿大癌症診斷人工智慧（AI）市場
  • 墨西哥癌症診斷領域的人工智慧（AI）市場
  • 歐洲癌症診斷人工智慧（AI）市場
  • 英國人工智慧（AI）在癌症診斷領域的市場
  • 德國癌症診斷人工智慧（AI）市場
  • 法國癌症診斷領域的人工智慧（AI）市場
  • 義大利癌症診斷人工智慧（AI）市場
  • 西班牙癌症診斷人工智慧（AI）市場
  • 其他歐洲人工智慧（AI）市場在癌症診斷領域的應用
  • 亞太地區癌症診斷人工智慧（AI）市場
  • 中國人工智慧（AI）在癌症診斷領域的市場
  • 日本癌症診斷領域的人工智慧（AI）市場
  • 印度癌症診斷領域的人工智慧（AI）市場
  • 澳洲癌症診斷人工智慧（AI）市場
  • 韓國癌症診斷領域的人工智慧（AI）市場
  • 亞太地區其他人工智慧（AI）市場在癌症診斷領域的應用
  • 世界其他地區人工智慧（AI）在癌症診斷領域的市場
  • 南美洲癌症診斷人工智慧（AI）市場
  • 中東癌症診斷人工智慧（AI）市場
  • 非洲癌症診斷人工智慧（AI）市場

影響分析：人工智慧的創新與應用：

人工智慧驅動的創新和應用正在改變癌症診斷格局，顯著提升疾病檢測和管理的準確性、效率和個人化程度。先進的機器學習和深度學習演算法正日益融入磁振造影（MRI）、電腦斷層掃描（CT）和正子斷層掃描（PET）等影像技術，有助於提高癌症早期檢出率、實現影像自動判讀並最大限度地減少診斷錯誤。人工智慧驅動的工具能夠分析包括基因組、蛋白質組和組織病理學資訊在內的複雜資料集，從而識別生物標記並預測治療反應，為精準腫瘤學鋪平道路。

自然語言處理 (NLP) 應用正在革新數據管理，它能夠從電子健康記錄、病理報告和臨床筆記中提取有價值的資訊，從而支持臨床決策並減輕醫生的工作量。此外，基於人工智慧的預測分析的引入實現了即時風險評估和患者分層，幫助臨床醫生更有效地制定治療方法。雲端運算、聯邦學習和邊緣人工智慧的持續進步，進一步實現了跨機構安全、可擴展的協作模式開發，同時也保障了病患隱私。因此，將人工智慧驅動的創新應用於癌症診斷，不僅能夠加快診斷流程、提高預後準確性，還能推動癌症診療模式轉移。

美國關稅對癌症診斷領域人工智慧（AI）市場的影響分析：

美國關稅政策可能透過影響成本、供應鏈和創新週期，對人工智慧（AI）在癌症診斷領域的市場成長和競爭力產生重大影響。對半導體、GPU、診斷成像硬體和檢測試劑等進口零件徵收關稅，會增加開發基於人工智慧的診斷工具的公司的生產和營運成本。這些增加的成本可能會轉嫁給醫院、實驗室，最終轉嫁給患者，減緩人工智慧技術在腫瘤學領域的廣泛應用。特別是小型Start-Ups企業，在這樣的條件下可能難以維持創新，因為不斷上漲的硬體和資料處理成本限制了它們高效訓練和更新模型的能力。同時，關稅可能會鼓勵對國內製造業和區域供應鏈的投資，從而增強長期韌性並降低對進口的依賴。然而，向本地化生產轉型需要大量的時間和資金投入，這可能會造成暫時的供應限制。

此外，診斷成本的上升可能會影響報銷決策，因為支付方和醫療系統會越來越謹慎地考慮是否要承擔昂貴的AI驅動檢測費用。為了應對這些課題，各公司正在探索平衡成本和維持創新的策略，例如擴大雲端基礎營運、申請研究工具的關稅豁免以及建立國際夥伴關係。簡而言之，雖然美國關稅旨在保護國內產業，但對癌症診斷AI市場的短期影響令人擔憂：成本上升和創新放緩。然而，從長遠來看，這些關稅可能會增強國內技術基礎。

目錄

第1章 人工智慧（AI）在癌症診斷市場報告概述

  • 調查範圍
  • 市場區隔
  • 市場假設

2. 人工智慧（AI）在癌症診斷市場的摘要整理

  • 市場概覽

第3章：人工智慧（AI）在癌症診斷市場的關鍵因素分析

  • 市場促進因素
    • 癌症發生率上升
    • 加強醫療圖像與人工智慧在癌症診斷中的融合
    • 全球主要市場參與企業的策略活動日益增多
  • 市場阻礙與課題
    • 數據可用性和品質有限
    • 嚴格的規章制度和道德考量
  • 市場機遇
    • 雲端運算和基於人工智慧的軟體即服務（SaaS）模式的興起

第4章 影響分析

  • 人工智慧驅動的創新和應用
  • 美國關稅的影響分析

第5章 監理分析

  • 美國
  • 歐洲
  • 日本
  • 中國

6. 人工智慧（AI）在癌症診斷市場的應用：波特五力分析

第7章 人工智慧（AI）在癌症診斷領域的市場評估

  • 按組件
    • 軟體
    • 服務
  • 按癌症類型
    • 乳癌
    • 肺癌
    • 大腸直腸癌
    • 攝護腺癌
    • 腦和神經系統癌症
    • 其他
  • 最終用戶
    • 醫院
    • 診斷中心
  • 地區
    • 北美洲
    • 歐洲
    • 亞太地區
    • 其他地區

第8章 競爭情勢

第9章Start-Ups資金籌措與投資趨勢

第10章 癌症診斷市場人工智慧（AI）公司及產品概況

  • iCAD, Inc.
  • ibex-ai
  • Roche Diagnostics
  • Kheiron Medical Technologies Limited
  • MVision AI Inc.
  • Siemens Healthineers AG
  • GE HealthCare
  • NVIDIA Corporation
  • Digital Diagnostics Inc.
  • IBM Corporation
  • Azra AI
  • ConcertAI
  • PathAI
  • Median Technologies
  • Paige AI Inc.
  • Therapixel
  • Flatiron,
  • Freenome Holdings Inc.
  • Onc.AI
  • Sonrai Analytics

第11章：KOL視角

第12章計劃方法

第13章：關於 DelveInsight

第14章 免責聲明和聯絡我們

Product Code: DIMDCL0845

Artificial Intelligence (AI) in Cancer Diagnostics Market Summary

  • The global Artificial Intelligence (AI) in Cancer Diagnostics market is expected to increase from USD 1,049.18 million in 2024 to USD 2,434.32 million by 2032, reflecting strong and sustained growth.
  • The global Artificial Intelligence (AI) in Cancer Diagnostics market is growing at a CAGR of 11.16% during the forecast period from 2025 to 2032.
  • The global Artificial Intelligence (AI) in Cancer Diagnostics market is growing rapidly due to rising cancer incidence, which drives demand for early and accurate detection. Increased integration of AI with medical imaging, including CT scans, MRIs, mammograms, and pathology slides, enhances diagnostic precision, reduces errors, and enables personalized treatment. Strategic initiatives by key market players, such as product launches, collaborations, and acquisitions, are further expanding technological capabilities and market reach. Together, these factors are accelerating AI adoption, improving patient outcomes, and transforming cancer diagnostics.
  • The leading companies operating in the Artificial Intelligence (AI) in Cancer Diagnostics market include iCAD, Inc., ibex-ai, Roche Diagnostics, Kheiron Medical Technologies Limited, MVision AI Inc., Siemens Healthineers AG, GE HealthCare, NVIDIA Corporation, Digital Diagnostics Inc., IBM Corporation, Azra AI, ConcertAI, PathAI, Median Technologies, Paige AI Inc., Therapixel, Flatiron, Freenome Holdings Inc., Onc.AI, Sonrai Analytics, and Others.
  • North America is expected to remain a dominant force in the Artificial Intelligence (AI) in Cancer Diagnostics market. This can be attributed to the region's high cancer prevalence, increasing demand for advanced diagnostic solutions, strong government support, and substantial investments in AI-driven healthcare technologies. The presence of leading AI developers and prominent medical imaging companies further fuels market expansion. The integration of AI with electronic health records (EHRs), precision medicine, and digital pathology is significantly enhancing the efficiency, accuracy, and speed of cancer detection and diagnosis across the region.
  • In the component segment of the Artificial Intelligence (AI) in Cancer Diagnostics market, the software category is estimated to account for the largest market share in 2024.

Factors Contributing to the Growth of Artificial Intelligence (AI) in Cancer Diagnostics Market

  • The Rising Cancer Incidence: The growing incidence of cancer worldwide is a major driver of the Artificial Intelligence (AI) in cancer diagnostics market. As the number of new cancer cases continues to rise, healthcare systems face increasing pressure to provide timely and accurate diagnoses. This urgent need is prompting hospitals and diagnostic centers to adopt AI-based solutions that can detect cancer early, improve prognostic accuracy, and support effective treatment planning. The increasing disease burden directly fuels demand for advanced diagnostic technologies, positioning AI as a critical tool in modern oncology care.
  • Increase integration of AI with medical imaging for cancer diagnostics: The integration of AI with medical imaging modalities such as CT scans, MRIs, mammograms, and pathology slides is enhancing the precision, efficiency, and reliability of cancer diagnostics. AI algorithms can process and analyze large volumes of complex imaging data quickly, identify subtle abnormalities that may be missed by human radiologists, and reduce false positives and negatives. This capability not only accelerates diagnosis but also supports personalized treatment planning, ultimately improving patient outcomes and optimizing clinical workflows across healthcare institutions..
  • Increase in strategic activities among the key market players across the globe: Strategic activities by key market players, including product launches, mergers, acquisitions, and collaborations, are playing a significant role in shaping the AI in cancer diagnostics market. These initiatives enable companies to expand their technological capabilities, develop innovative AI-driven diagnostic solutions, and extend their global market presence. Collaborative efforts with research institutions, hospitals, and technology providers also accelerate the commercialization of cutting-edge AI tools, fostering innovation and strengthening the adoption of AI technologies in oncology care worldwide.

Artificial Intelligence (AI) in Cancer Diagnostics Market Report Segmentation

This Artificial Intelligence (AI) in Cancer Diagnostics market report offers a comprehensive overview of the global Artificial Intelligence (AI) in Cancer Diagnostics market, highlighting key trends, growth drivers, challenges, and opportunities. It covers detailed market segmentation by Component (Software and Services), Cancer Type (Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Brain & Nervous System Cancers, and Others), End-Users (Hospitals, Diagnostic Centers, and Others), and Geography. The report provides valuable insights into the competitive landscape, regulatory environment, and market dynamics across major markets, including North America, Europe, and Asia-Pacific. Featuring in-depth profiles of leading industry players and recent product innovations, this report equips businesses with essential data to identify market potential, develop strategic plans, and capitalize on emerging opportunities in the rapidly growing Artificial Intelligence (AI) in Cancer Diagnostics market.

Artificial Intelligence (AI) in Cancer Diagnostics refers to the use of advanced computational algorithms, machine learning, and data-driven models to analyze medical data such as imaging, lab results, and patient records to assist in disease detection, diagnosis, and prognosis. By recognizing patterns and anomalies often undetectable to the human eye, AI improves diagnostic accuracy, accelerates decision-making, and supports personalized treatment planning, enhancing patient outcomes and streamlining clinical workflows.

The growth of Artificial Intelligence (AI) in cancer diagnostics market is being driven by multiple interrelated factors. The rising incidence of cancer worldwide is creating an urgent need for early and accurate detection, prompting healthcare providers to adopt advanced AI-powered diagnostic solutions that can improve prognostic accuracy and support effective treatment planning. Simultaneously, the increasing integration of AI with medical imaging modalities, including CT scans, MRIs, mammograms, and pathology slides, is enhancing diagnostic precision and efficiency.

AI algorithms can rapidly analyze large volumes of complex imaging data, detect subtle abnormalities that may be overlooked by human radiologists, and reduce false positives and negatives, thereby accelerating diagnosis and enabling personalized treatment strategies. In addition, strategic activities among key market players, such as product launches, mergers, acquisitions, and collaborations, are further strengthening the market. These initiatives expand technological capabilities, foster innovation, and broaden the global reach of AI-driven cancer diagnostic solutions.

Collectively, these factors are driving the rapid adoption of AI in oncology, improving patient outcomes, optimizing clinical workflows, and transforming the landscape of cancer diagnostics worldwide.

What are the latest Artificial Intelligence (AI) in Cancer Diagnostics Market Dynamics and Trends?

The artificial intelligence in cancer diagnostics market is experiencing substantial growth, driven by the rising incidence of cancer and the increasing demand for early and accurate detection. The integration of AI with medical imaging technologies, including CT scans, MRIs, mammograms, and pathology slides, is enhancing diagnostic precision, minimizing errors, and enabling personalized treatment strategies. Strategic initiatives by leading market players, such as product launches, partnerships, and acquisitions, are further strengthening technological capabilities and expanding market presence. Collectively, these factors are driving widespread adoption of AI, improving patient outcomes, and transforming the landscape of cancer diagnostics globally.

Cancer continues to be a primary driver of market growth. According to DelveInsight analysis, the estimated number of new cancer cases worldwide is expected to reach 21.5 million in 2025, rising to 32.5 million by 2045. Breast cancer accounted for approximately 2.5 million new cases globally in 2025, projected to increase to 3.35 million by 2045, while prostate cancer cases are estimated at 1.55 million in 2025, expected to rise to 2.85 million by 2050. This growing global cancer burden is intensifying the demand for advanced diagnostic solutions, with AI playing a pivotal role in early detection, accuracy, and improving treatment outcomes. Traditional diagnostic methods, such as biopsies and manual interpretation of imaging, are often time-consuming and prone to human error. In contrast, AI-powered solutions automate detection, analyze vast datasets from imaging modalities, and integrate genomic and patient data to support oncologists in developing personalized treatment plans.

The integration of AI with medical imaging is revolutionizing cancer diagnostics by enhancing accuracy, efficiency, and early detection. AI-driven imaging solutions, leveraging deep learning algorithms and computer vision, can detect patterns and anomalies that may be overlooked by human observers. These technologies improve image segmentation, lesion detection, and tumor classification, enabling earlier and more precise diagnoses. Advanced AI models can differentiate between benign and malignant tumors with higher sensitivity and specificity, reducing false positives and unnecessary biopsies. Additionally, AI-powered tools assist in monitoring tumor progression, evaluating treatment responses, and predicting disease recurrence, empowering oncologists to make informed decisions for individualized patient care.

Strategic initiatives by key market players are further accelerating market growth. For instance, in September 2024, Roche expanded its digital pathology platform by integrating over 20 advanced AI algorithms from eight new collaborators through its navify(R) Digital Pathology enterprise software. This initiative enhances cancer research and diagnostic capabilities, providing pathologists with seamless access to cutting-edge AI innovations and strengthening the adoption of AI solutions in clinical practice.

Thus, the combination of rising cancer prevalence, continuous technological innovations, and proactive industry strategies is expected to drive significant growth in the global AI in cancer diagnostics market throughout the forecast period, reshaping oncology care and improving diagnostic precision worldwide.

However, the growth of the global Artificial Intelligence (AI) in cancer diagnostics market, particularly in the machine learning and oncology segments, faces significant challenges. Limited data availability and variable quality pose major obstacles, as AI systems require large, high-quality datasets to train algorithms effectively. Inconsistent or incomplete medical imaging, genomic, and clinical data can compromise model accuracy and reduce diagnostic reliability. Additionally, strict regulatory and ethical concerns further constrain market expansion. AI-driven diagnostic tools must undergo extensive clinical validation to demonstrate safety, accuracy, and efficacy, and navigating complex regulatory frameworks across multiple regions can delay approvals and product launches. Ethical considerations, including patient consent, data privacy, and equitable access, add another layer of complexity to implementation.

Collectively, limited data quality and availability, combined with stringent regulatory and ethical requirements, restrict the full potential of AI in cancer diagnostics, even as these technologies continue to enhance early detection, improve workflow efficiency, and support precision medicine initiatives in oncology.

Artificial Intelligence (AI) in Cancer Diagnostics Market Segment Analysis

Artificial Intelligence (AI) in Cancer Diagnostics Market by Component (Software and Services), Cancer Type (Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Brain & Nervous System Cancers, and Others), End-Users (Hospitals, Diagnostic Centers, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World)

Artificial Intelligence (AI) in Cancer Diagnostics Market Regional Analysis

North America Artificial Intelligence (AI) in Cancer Diagnostics Market Trends

North America, led by the U.S., accounted for a dominant 51% share of the global Artificial Intelligence (AI) in Cancer Diagnostics market in 2024. North America's dominance in the artificial intelligence (AI) in cancer diagnostics market can be attributed to the region's high cancer prevalence, increasing demand for advanced diagnostic solutions, strong government support, and substantial investments in AI-driven healthcare technologies. The presence of leading AI developers and prominent medical imaging companies further fuels market expansion. The integration of AI with electronic health records (EHRs), precision medicine, and digital pathology is significantly enhancing the efficiency, accuracy, and speed of cancer detection and diagnosis across the region.

According to DelveInsight (2025), North America is projected to record approximately 2.9 million new cancer cases in 2025, rising to 3.85 million by 2045. Breast cancer, a major contributor to the overall cancer burden, accounted for around 325,000 new cases in 2025, with numbers expected to increase to 385,000 by 2045. AI-powered diagnostic solutions are playing a critical role in breast cancer detection by analyzing mammograms, ultrasounds, and MRI scans with remarkable precision. These technologies not only reduce false positives and negatives but also enhance diagnostic confidence. Advanced machine learning algorithms can identify subtle imaging patterns that may be overlooked by human radiologists, enabling earlier and more accurate diagnoses. Additionally, AI supports comprehensive risk assessment, tumor classification, and personalized treatment planning by integrating imaging data with genomic and clinical information.

The North American market is further strengthened by strategic initiatives among key industry players, including mergers and acquisitions, regulatory approvals, and new product launches. These activities accelerate technological advancements, expand product portfolios, and reinforce market presence, facilitating the introduction of innovative AI-driven solutions for cancer detection and treatment. For instance, in October 2023, Philips partnered with Quibim, a specialist in imaging biomarkers, to launch AI-powered imaging and reporting solutions for magnetic resonance (MR) prostate screenings. Collaborations of this nature are instrumental in advancing diagnostic capabilities and addressing the region's growing healthcare demands.

Thus, the combination of rising cancer incidence, continuous technological innovation, supportive regulatory frameworks, and proactive industry strategies is expected to propel the AI in cancer diagnostics market in North America throughout the forecast period from 2025 to 2032.

Europe Artificial Intelligence (AI) in Cancer Diagnostics Market Trends

The Europe artificial intelligence (AI) in cancer diagnostics market is experiencing steady growth, supported by well-established healthcare systems, strong research and development capabilities, and favorable government policies promoting digital health adoption. Countries such as Germany, the United Kingdom, France, and the Netherlands are leading the adoption of AI-powered diagnostic tools, particularly in imaging, pathology, and predictive analytics, to enhance early cancer detection, improve diagnostic accuracy, and support personalized treatment strategies.

Collaborative initiatives between hospitals, academic institutions, and technology providers are fostering innovation and accelerating the commercialization of AI solutions. Regulatory frameworks, including the European Union's Medical Device Regulation (MDR) and guidelines on AI in healthcare, are shaping market dynamics by ensuring safety, efficacy, and interoperability of AI-based diagnostic systems. Additionally, the growing integration of cloud computing, big data analytics, and telehealth solutions is enabling scalable and efficient deployment of AI tools across clinical settings. Startups and mid-sized companies are actively contributing to market growth through niche AI applications and innovative platforms, while established players continue to leverage their extensive data resources and technological expertise.

Hence, the European market is marked by a balanced interplay between innovation, regulatory compliance, and technological sophistication, driving the widespread adoption of AI in cancer diagnostics and reinforcing Europe's position as a key player in the global landscape.

Asia-Pacific Artificial Intelligence (AI) in Cancer Diagnostics Market Trends

The Asia-Pacific artificial intelligence (AI) in cancer diagnostics market is witnessing rapid growth, driven by rising cancer prevalence, increasing healthcare expenditure, and the adoption of advanced digital technologies across the region. Countries such as China, Japan, India, and South Korea are emerging as key hubs for AI-driven diagnostic solutions due to significant investments in healthcare infrastructure, government initiatives promoting AI integration, and a growing pool of skilled professionals in data science and medical imaging.

AI applications in imaging, pathology, and genomics are being increasingly utilized to enhance early detection, improve diagnostic accuracy, and enable personalized treatment planning. Collaborations between hospitals, research institutions, and technology providers are accelerating the development and deployment of locally relevant AI solutions, while startups are focusing on cost-effective, scalable platforms to address the diverse healthcare needs of the region. Regulatory frameworks are evolving to accommodate AI-based medical technologies, with authorities emphasizing clinical validation, data privacy, and interoperability standards, thereby fostering greater trust and adoption. Moreover, the integration of cloud computing, telemedicine, and mobile diagnostic tools is expanding access to AI-enabled cancer diagnostics, particularly in rural and underserved areas.

Therefore, the Asia-Pacific market is characterized by dynamic innovation, increasing public and private sector investment, and a strong focus on localized, patient-centric AI solutions, positioning the region as a rapidly growing contributor to the global AI in cancer diagnostics landscape.

Who are the major players in the Artificial Intelligence (AI) in Cancer Diagnostics Market?

The following are the leading companies in the Artificial Intelligence (AI) in Cancer Diagnostics market. These companies collectively hold the largest market share and dictate industry trends.

  • iCAD, Inc.
  • ibex-ai
  • Roche Diagnostics
  • Kheiron Medical Technologies Limited
  • MVision AI Inc.
  • Siemens Healthineers AG
  • GE HealthCare
  • NVIDIA Corporation
  • Digital Diagnostics Inc.
  • IBM Corporation
  • Azra AI
  • ConcertAI
  • PathAI
  • Median Technologies
  • Paige AI Inc.
  • Therapixel
  • Flatiron
  • Freenome Holdings Inc.
  • Onc.AI
  • Sonrai Analytics

How is the competitive landscape shaping the Artificial Intelligence (AI) in Cancer Diagnostics market?

The competitive landscape of the artificial intelligence (AI) in cancer diagnostics market is moderately concentrated, characterized by the presence of a few dominant players alongside a growing number of emerging startups driving innovation. Established companies such as IBM Watson Health, Google Health, Siemens Healthineers, GE HealthCare, and Philips are leveraging their strong R&D capabilities, extensive data ecosystems, and partnerships with healthcare institutions to strengthen their market positions.

These firms are actively integrating AI into existing imaging and diagnostic platforms, expanding their oncology-focused product portfolios, and investing in predictive analytics and precision medicine solutions. Meanwhile, startups and mid-sized firms are contributing to market dynamism through specialized AI algorithms, cloud-based diagnostic platforms, and advanced pathology solutions targeting niche cancer types.

Strategic collaborations, mergers and acquisitions, and venture funding are becoming key growth strategies, enabling players to enhance their technological depth and expand geographically. Furthermore, the rising demand for interoperable and regulatory-compliant AI tools has prompted companies to prioritize FDA clearances, CE markings, and clinical validation studies to build market credibility. Despite the dominance of major players, the market remains open to innovation, with AI-driven advancements in multi-modal diagnostics, real-time image interpretation, and biomarker discovery creating opportunities for new entrants.

Hence, the competitive landscape reflects a balance between established global leaders and agile innovators, collectively accelerating the adoption of AI technologies in cancer diagnostics while maintaining a moderately concentrated market structure.

Recent Developmental Activities in Artificial Intelligence (AI) in Cancer Diagnostics Market

  • In August 2025, Esaote announced FDA approval of its MyLab(TM) A50 and MyLab(TM) A70 ultrasound systems. Previously unveiled internationally, these portable, high-performance imaging platforms are now cleared for U.S. distribution, marking a key milestone in Esaote's commitment to innovation in diagnostic imaging.
  • In August 2025, the FDA granted De Novo authorization to ArteraAI Prostate, making it the first AI-powered Software as a Medical Device for prognosticating long-term outcomes in non-metastatic prostate cancer.

Artificial Intelligence (AI) in Cancer Diagnostics Market Segmentation

  • Artificial Intelligence (AI) in Cancer Diagnostics by Component Exposure
  • Software
  • Services
  • Artificial Intelligence (AI) in Cancer Diagnostics Application Exposure
  • Breast Cancer
  • Lung Cancer
  • Colorectal Cancer
  • Prostate Cancer
  • Brain & Nervous System Cancers
  • Others
  • Artificial Intelligence (AI) in Cancer Diagnostics End-Users Exposure
  • Hospitals
  • Diagnostic Centre
  • Others
  • Artificial Intelligence (AI) in Cancer Diagnostics Geography Exposure
  • North America Artificial Intelligence (AI) in Cancer Diagnostics Market
  • United States Artificial Intelligence (AI) in Cancer Diagnostics Market
  • Canada Artificial Intelligence (AI) in Cancer Diagnostics Market
  • Mexico Artificial Intelligence (AI) in Cancer Diagnostics Market
  • Europe Artificial Intelligence (AI) in Cancer Diagnostics Market
  • United Kingdom Artificial Intelligence (AI) in Cancer Diagnostics Market
  • Germany Artificial Intelligence (AI) in Cancer Diagnostics Market
  • France Artificial Intelligence (AI) in Cancer Diagnostics Market
  • Italy Artificial Intelligence (AI) in Cancer Diagnostics Market
  • Spain Artificial Intelligence (AI) in Cancer Diagnostics Market
  • Rest of Europe Artificial Intelligence (AI) in Cancer Diagnostics Market
  • Asia-Pacific Artificial Intelligence (AI) in Cancer Diagnostics Market
  • China Artificial Intelligence (AI) in Cancer Diagnostics Market
  • Japan Artificial Intelligence (AI) in Cancer Diagnostics Market
  • India Artificial Intelligence (AI) in Cancer Diagnostics Market
  • Australia Artificial Intelligence (AI) in Cancer Diagnostics Market
  • South Korea Artificial Intelligence (AI) in Cancer Diagnostics Market
  • Rest of Asia-Pacific Artificial Intelligence (AI) in Cancer Diagnostics Market
  • Rest of the World Artificial Intelligence (AI) in Cancer Diagnostics Market
  • South America Artificial Intelligence (AI) in Cancer Diagnostics Market
  • Middle East Artificial Intelligence (AI) in Cancer Diagnostics Market
  • Africa Artificial Intelligence (AI) in Cancer Diagnostics Market

Impact Analysis

AI-Powered Innovations and Applications:

AI-powered innovations and applications are transforming the landscape of cancer diagnostics by enhancing accuracy, efficiency, and personalization in disease detection and management. Advanced machine learning and deep learning algorithms are increasingly being integrated into imaging modalities such as MRI, CT, and PET scans to improve early cancer detection, automate image interpretation, and minimize diagnostic errors. AI-driven tools can analyze complex datasets, including genomic, proteomic, and histopathological information, to identify biomarkers and predict treatment responses, paving the way for precision oncology.

Natural language processing (NLP) applications are also revolutionizing data management by extracting valuable insights from electronic health records, pathology reports, and clinical notes, thereby supporting clinical decision-making and reducing physician workload. Moreover, the adoption of AI-based predictive analytics enables real-time risk assessment and patient stratification, helping clinicians tailor therapies more effectively. Continuous advancements in cloud computing, federated learning, and edge AI are further enabling secure, scalable, and collaborative model development across institutions without compromising patient privacy. Therefore, the integration of AI-powered innovations in cancer diagnostics is not only accelerating diagnostic workflows and improving prognostic accuracy but also driving a paradigm shift toward data-driven, patient-centric oncology care.

U.S. Tariff Impact Analysis on the Artificial Intelligence (AI) in Cancer Diagnostics Market:

U.S. tariff policies can significantly influence the growth and competitiveness of artificial intelligence (AI) in cancer diagnostics market by affecting costs, supply chains, and innovation cycles. Tariffs imposed on imported components such as semiconductors, GPUs, imaging hardware, or laboratory reagents increase production and operational expenses for companies developing AI-based diagnostic tools. This escalation in costs often leads to higher prices for hospitals, laboratories, and ultimately patients, potentially slowing the adoption of AI technologies in oncology. Smaller startups may find it especially difficult to sustain innovation under these conditions, as rising hardware and data processing costs can limit their ability to train and update models efficiently. On the other hand, tariff measures may encourage domestic manufacturing and investment in local supply chains, enhancing long-term resilience and reducing reliance on imports. However, transitioning to local production requires substantial time and capital investment, which may cause temporary supply constraints.

Additionally, higher diagnostic costs may influence reimbursement decisions, as payers and healthcare systems become more cautious about covering expensive AI-driven tests. To mitigate these challenges, companies are exploring strategies such as expanding cloud-based operations, seeking tariff exemptions for research tools, or forming international partnerships to balance costs and maintain innovation momentum. In essence, while U.S. tariffs aim to protect domestic industries, their short-term impact on the AI in cancer diagnostics market may include higher costs and slower innovation, even as they potentially strengthen domestic technological capacity over the long term.

How This Analysis Helps Clients

  • Cost Management: By understanding the tariff landscape, clients can anticipate cost increases and adjust pricing strategies accordingly, ensuring profitability.
  • Supply Chain Optimization: Clients can identify alternative sourcing options and diversify their supply chains to reduce dependency on high-tariff regions, enhancing resilience.
  • Regulatory Navigation: Expert guidance on navigating the evolving regulatory environment helps clients maintain compliance and avoid potential legal challenges.
  • Strategic Planning: Insights into tariff impacts enable clients to make informed decisions about manufacturing locations, partnerships, and market entry strategies.

Key takeaways from the Artificial Intelligence (AI) in Cancer Diagnostics market report study

  • Market size analysis for the current Artificial Intelligence (AI) in Cancer Diagnostics market size (2024), and market forecast for 8 years (2025 to 2032)
  • Top key product/technology developments, mergers, acquisitions, partnerships, and joint ventures happened over the last 3 years.
  • Key companies dominating the Artificial Intelligence (AI) in Cancer Diagnostics market.
  • Various opportunities available for the other competitors in the Artificial Intelligence (AI) in Cancer Diagnostics market space.
  • What are the top-performing segments in 2024? How these segments will perform in 2032?
  • Which are the top-performing regions and countries in the Artificial Intelligence (AI) in Cancer Diagnostics market scenario?
  • Which are the regions and countries where companies should have concentrated on opportunities for Artificial Intelligence (AI) in Cancer Diagnostics market growth in the future?

Frequently Asked Questions for Artificial Intelligence (AI) in Cancer Diagnostics Market

1. What is the growth rate of Artificial Intelligence (AI) in Cancer Diagnostics market?

  • The Artificial Intelligence (AI) in Cancer Diagnostics market is estimated to grow at a CAGR of 11.16% during the forecast period from 2025 to 2032.

2. What is the market for Artificial Intelligence (AI) in Cancer Diagnostics?

  • The Artificial Intelligence (AI) in Cancer Diagnostics market was valued at USD 1,049.18 million in 2024, and is expected to reach USD 2,434.32 million by 2032.

3. Which region has the highest share in the Artificial Intelligence (AI) in Cancer Diagnostics market?

  • North America is expected to remain a dominant force in the Artificial Intelligence (AI) in Cancer Diagnostics market. This can be attributed to the region's high cancer prevalence, increasing demand for advanced diagnostic solutions, strong government support, and substantial investments in AI-driven healthcare technologies. The presence of leading AI developers and prominent medical imaging companies further fuels market expansion. The integration of AI with electronic health records (EHRs), precision medicine, and digital pathology is significantly enhancing the efficiency, accuracy, and speed of cancer detection and diagnosis across the region.

4. What are the drivers for Artificial Intelligence (AI) in Cancer Diagnostics market?

  • The global Artificial Intelligence (AI) in Cancer Diagnostics market is growing rapidly due to rising cancer incidence, which drives demand for early and accurate detection. Increased integration of AI with medical imaging, including CT scans, MRIs, mammograms, and pathology slides, enhances diagnostic precision, reduces errors, and enables personalized treatment. Strategic initiatives by key market players, such as product launches, collaborations, and acquisitions, are further expanding technological capabilities and market reach. Together, these factors are accelerating AI adoption, improving patient outcomes, and transforming cancer diagnostics.

5. Who are the key players operating in the Artificial Intelligence (AI) in Cancer Diagnostics market?

  • Some of the key market players operating in the Artificial Intelligence (AI) in Cancer Diagnostics market include iCAD, Inc., ibex-ai, Roche Diagnostics, Kheiron Medical Technologies Limited, MVision AI Inc., Siemens Healthineers AG, GE HealthCare, NVIDIA Corporation, Digital Diagnostics Inc., IBM Corporation, Azra AI, ConcertAI, PathAI, Median Technologies, Paige AI Inc., Therapixel, Flatiron, Freenome Holdings Inc., Onc.AI, Sonrai Analytics, and Others.

Table of Contents

1. Artificial Intelligence (AI) in Cancer Diagnostics Market Report Introduction

  • 1.1 Scope of the Study
  • 1.2 Market Segmentation
  • 1.3 Market Assumption

2. Artificial Intelligence (AI) in Cancer Diagnostics Market Executive Summary

  • 2.1 Market at Glance

3. Artificial Intelligence (AI) in Cancer Diagnostics Market Key Factors Analysis

  • 3.1 Artificial Intelligence (AI) in Cancer Diagnostics Market Drivers
    • 3.1.1 The rising cancer incidence
    • 3.1.2 Increase the integration of AI with medical imaging for cancer diagnostics
    • 3.1.3 Increase in strategic activities among the key market players across the globe
  • 3.2 Artificial Intelligence (AI) in Cancer Diagnostics Market Restraints and Challenges
    • 3.2.1 Limited data availability and quality
    • 3.2.2 Strict regulatory and ethical concerns
  • 3.3 Artificial Intelligence (AI) in Cancer Diagnostics Market Opportunity
    • 3.3.1 The rise of cloud computing and AI-based SaaS (Software as a Service) models

4. Impact Analysis

  • 4.1 AI-Powered Innovations and Applications
  • 4.2 U.S. Tariff Impact Analysis

5. Regulatory Analysis

  • 5.1 The United States
  • 5.2 Europe
  • 5.3 Japan
  • 5.4 China

6. Artificial Intelligence (AI) in Cancer Diagnostics Market Porter's Five Forces Analysis

  • 6.1 Bargaining Power of Suppliers
  • 6.2 Bargaining Power of Consumers
  • 6.3 Threat of New Entrants
  • 6.4 Threat of Substitutes
  • 6.5 Competitive Rivalry

7. Artificial Intelligence (AI) in Cancer Diagnostics Market Assessment

  • 7.1 By Component
    • 7.1.1 Software
    • 7.1.2 Services
  • 7.2 By Cancer Type
    • 7.2.1 Breast Cancer
    • 7.2.2 Lung Cancer
    • 7.2.3 Colorectal Cancer
    • 7.2.4 Prostate Cancer
    • 7.2.5 Brain & Nervous System Cancers
    • 7.2.6 Others
  • 7.3 By End-Users
    • 7.3.1 Hospitals
    • 7.3.2 Diagnostic Centre
    • 7.3.3 Others
  • 7.4 By Geography
    • 7.4.1 North America
      • 7.4.1.1 United States Artificial Intelligence (AI) in Cancer Diagnostics Market Size in USD million (2022-2032)
      • 7.4.1.2 Canada Artificial Intelligence (AI) in Cancer Diagnostics Market Size in USD million (2022-2032)
      • 7.4.1.3 Mexico Artificial Intelligence (AI) in Cancer Diagnostics Market Size in USD million (2022-2032)
    • 7.4.2 Europe
      • 7.4.2.1 France Artificial Intelligence (AI) in Cancer Diagnostics Market Size in USD million (2022-2032)
      • 7.4.2.2 Germany Artificial Intelligence (AI) in Cancer Diagnostics Market Size in USD million (2022-2032)
      • 7.4.2.3 United Kingdom Artificial Intelligence (AI) in Cancer Diagnostics Market Size in USD million (2022-2032)
      • 7.4.2.4 Italy Artificial Intelligence (AI) in Cancer Diagnostics Market Size in USD million (2022-2032)
      • 7.4.2.5 Spain Artificial Intelligence (AI) in Cancer Diagnostics Market Size in USD million (2022-2032)
      • 7.4.2.6 Rest of Europe Artificial Intelligence (AI) in Cancer Diagnostics Market Size in USD million (2022-2032)
    • 7.4.3 Asia-Pacific
      • 7.4.3.1 China Artificial Intelligence (AI) in Cancer Diagnostics Market Size in USD million (2022-2032)
      • 7.4.3.2 Japan Artificial Intelligence (AI) in Cancer Diagnostics Market Size in USD million (2022-2032)
      • 7.4.3.3 India Artificial Intelligence (AI) in Cancer Diagnostics Market Size in USD million (2022-2032)
      • 7.4.3.4 Australia Artificial Intelligence (AI) in Cancer Diagnostics Market Size in USD million (2022-2032)
      • 7.4.3.5 South Korea Artificial Intelligence (AI) in Cancer Diagnostics Market Size in USD million (2022-2032)
      • 7.4.3.6 Rest of Asia-Pacific Artificial Intelligence (AI) in Cancer Diagnostics Market Size in USD million (2022-2032)
    • 7.4.4 Rest of the World (RoW)
      • 7.4.4.1 Middle East Artificial Intelligence (AI) in Cancer Diagnostics Market Size in USD million (2022-2032)
      • 7.4.4.2 Africa Artificial Intelligence (AI) in Cancer Diagnostics Market Size in USD million (2022-2032)
      • 7.4.4.3 South America Artificial Intelligence (AI) in Cancer Diagnostics Market Size In USD Million (2022-2032)

8. Competitive Landscape

9. Startup Funding & Investment Trends

10. Artificial Intelligence (AI) in Cancer Diagnostics Market Company and Product Profiles

  • 10.1 iCAD, Inc.
    • 10.1.1 Company Overview
    • 10.1.2 Company Snapshot
    • 10.1.3 Financial Overview
    • 10.1.4 Product Listing
    • 10.1.5 Entropy
  • 10.2 ibex-ai
    • 10.2.1 Company Overview
    • 10.2.2 Company Snapshot
    • 10.2.3 Financial Overview
    • 10.2.4 Product Listing
    • 10.2.5 Entropy
  • 10.3 Roche Diagnostics
    • 10.3.1 Company Overview
    • 10.3.2 Company Snapshot
    • 10.3.3 Financial Overview
    • 10.3.4 Product Listing
    • 10.3.5 Entropy
  • 10.4 Kheiron Medical Technologies Limited
    • 10.4.1 Company Overview
    • 10.4.2 Company Snapshot
    • 10.4.3 Financial Overview
    • 10.4.4 Product Listing
    • 10.4.5 Entropy
  • 10.5 MVision AI Inc.
    • 10.5.1 Company Overview
    • 10.5.2 Company Snapshot
    • 10.5.3 Financial Overview
    • 10.5.4 Product Listing
    • 10.5.5 Entropy
  • 10.6 Siemens Healthineers AG
    • 10.6.1 Company Overview
    • 10.6.2 Company Snapshot
    • 10.6.3 Financial Overview
    • 10.6.4 Product Listing
    • 10.6.5 Entropy
  • 10.7 GE HealthCare
    • 10.7.1 Company Overview
    • 10.7.2 Company Snapshot
    • 10.7.3 Financial Overview
    • 10.7.4 Product Listing
    • 10.7.5 Entropy
  • 10.8 NVIDIA Corporation
    • 10.8.1 Company Overview
    • 10.8.2 Company Snapshot
    • 10.8.3 Financial Overview
    • 10.8.4 Product Listing
    • 10.8.5 Entropy
  • 10.9 Digital Diagnostics Inc.
    • 10.9.1 Company Overview
    • 10.9.2 Company Snapshot
    • 10.9.3 Financial Overview
    • 10.9.4 Product Listing
    • 10.9.5 Entropy
  • 10.10 IBM Corporation
    • 10.10.1 Company Overview
    • 10.10.2 Company Snapshot
    • 10.10.3 Financial Overview
    • 10.10.4 Product Listing
    • 10.10.5 Entropy
  • 10.11 Azra AI
    • 10.11.1 Company Overview
    • 10.11.2 Company Snapshot
    • 10.11.3 Financial Overview
    • 10.11.4 Product Listing
    • 10.11.5 Entropy
  • 10.12 ConcertAI
    • 10.12.1 Company Overview
    • 10.12.2 Company Snapshot
    • 10.12.3 Financial Overview
    • 10.12.4 Product Listing
    • 10.12.5 Entropy
  • 10.13 PathAI
    • 10.13.1 Company Overview
    • 10.13.2 Company Snapshot
    • 10.13.3 Financial Overview
    • 10.13.4 Product Listing
    • 10.13.5 Entropy
  • 10.14 Median Technologies
    • 10.14.1 Company Overview
    • 10.14.2 Company Snapshot
    • 10.14.3 Financial Overview
    • 10.14.4 Product Listing
    • 10.14.5 Entropy
  • 10.15 Paige AI Inc.
    • 10.15.1 Company Overview
    • 10.15.2 Company Snapshot
    • 10.15.3 Financial Overview
    • 10.15.4 Product Listing
    • 10.15.5 Entropy
  • 10.16 Therapixel
    • 10.16.1 Company Overview
    • 10.16.2 Company Snapshot
    • 10.16.3 Financial Overview
    • 10.16.4 Product Listing
    • 10.16.5 Entropy
  • 10.17 Flatiron,
    • 10.17.1 Company Overview
    • 10.17.2 Company Snapshot
    • 10.17.3 Financial Overview
    • 10.17.4 Product Listing
    • 10.17.5 Entropy
  • 10.18 Freenome Holdings Inc.
    • 10.18.1 Company Overview
    • 10.18.2 Company Snapshot
    • 10.18.3 Financial Overview
    • 10.18.4 Product Listing
    • 10.18.5 Entropy
  • 10.19 Onc.AI
    • 10.19.1 Company Overview
    • 10.19.2 Company Snapshot
    • 10.19.3 Financial Overview
    • 10.19.4 Product Listing
    • 10.19.5 Entropy
  • 10.20 Sonrai Analytics
    • 10.20.1 Company Overview
    • 10.20.2 Company Snapshot
    • 10.20.3 Financial Overview
    • 10.20.4 Product Listing
    • 10.20.5 Entropy

11. KOL Views

12. Project Approach

13. About DelveInsight

14. Disclaimer & Contact Us

List of Tables

  • Table 1: Artificial Intelligence (AI) in Cancer Diagnostics Market in Global (2022-2032)
  • Table 2: Artificial Intelligence (AI) in Cancer Diagnostics Market in Global by Component (2022-2032)
  • Table 3: Artificial Intelligence (AI) in Cancer Diagnostics Market in Global by Cancer Type (2022-2032)
  • Table 4: Artificial Intelligence (AI) in Cancer Diagnostics Market in Global by End-Users (2022-2032)
  • Table 5: Artificial Intelligence (AI) in Cancer Diagnostics Market in Global by Geography (2022-2032)
  • Table 6: Artificial Intelligence (AI) in Cancer Diagnostics Market in North America (2022-2032)
  • Table 7: Artificial Intelligence (AI) in Cancer Diagnostics Market in the United States (2022-2032)
  • Table 8: Artificial Intelligence (AI) in Cancer Diagnostics Market in Canada (2022-2032)
  • Table 9: Artificial Intelligence (AI) in Cancer Diagnostics Market in Mexico (2022-2032)
  • Table 10: Artificial Intelligence (AI) in Cancer Diagnostics Market in Europe (2022-2032)
  • Table 11: Artificial Intelligence (AI) in Cancer Diagnostics Market in France (2022-2032)
  • Table 12: Artificial Intelligence (AI) in Cancer Diagnostics Market in Germany (2022-2032)
  • Table 13: Artificial Intelligence (AI) in Cancer Diagnostics Market in United Kingdom (2022-2032)
  • Table 14: Artificial Intelligence (AI) in Cancer Diagnostics Market in Italy (2022-2032)
  • Table 15: Artificial Intelligence (AI) in Cancer Diagnostics Market in Spain (2022-2032)
  • Table 16: Artificial Intelligence (AI) in Cancer Diagnostics Market in the Rest of Europe (2022-2032)
  • Table 17: Artificial Intelligence (AI) in Cancer Diagnostics Market in Asia-Pacific (2022-2032)
  • Table 18: Artificial Intelligence (AI) in Cancer Diagnostics Market in China (2022-2032)
  • Table 19: Artificial Intelligence (AI) in Cancer Diagnostics Market in Japan (2022-2032)
  • Table 20: Artificial Intelligence (AI) in Cancer Diagnostics Market in India (2022-2032)
  • Table 21: Artificial Intelligence (AI) in Cancer Diagnostics Market in Australia (2022-2032)
  • Table 22: Artificial Intelligence (AI) in Cancer Diagnostics Market in South Korea (2022-2032)
  • Table 23: Artificial Intelligence (AI) in Cancer Diagnostics Market in Rest of Asia-Pacific (2022-2032)
  • Table 24: Artificial Intelligence (AI) in Cancer Diagnostics Market in the Rest of the World (2022-2032)
  • Table 25: Artificial Intelligence (AI) in Cancer Diagnostics Market in the Middle East (2022-2032)
  • Table 26: Artificial Intelligence (AI) in Cancer Diagnostics Market in Africa (2022-2032)
  • Table 27: Artificial Intelligence (AI) in Cancer Diagnostics Market in South America (2022-2032)
  • Table 28: Competitive Landscape
  • Table 29: Startup Funding & Investment Trends

List of Figures

  • Table 1: Artificial Intelligence (AI) in Cancer Diagnostics Market Drivers
  • Table 2: Artificial Intelligence (AI) in Cancer Diagnostics Market Restraints
  • Table 3: Artificial Intelligence (AI) in Cancer Diagnostics Market Opportunities
  • Table 4: AI-Powered Innovations in Artificial Intelligence (AI) in Cancer Diagnostics Market
  • Table 5: US Tariff Impact on Artificial Intelligence (AI) in Cancer Diagnostics Market
  • Table 6: Regulatory Analysis (US, EU, Japan, China)
  • Table 7: Porter's Five Forces Analysis
  • Table 8: Competitive Analysis
  • Table 9: Artificial Intelligence (AI) in Cancer Diagnostics Market in Global (2022-2032)
  • Table 10: Artificial Intelligence (AI) in Cancer Diagnostics Market in Global by Component (2022-2032)
  • Table 11: Artificial Intelligence (AI) in Cancer Diagnostics Market in Global by Cancer Type (2022-2032)
  • Table 12: Artificial Intelligence (AI) in Cancer Diagnostics Market in Global by End-Users (2022-2032)
  • Table 13: Artificial Intelligence (AI) in Cancer Diagnostics Market in Global by Geography (2022-2032)
  • Table 14: Artificial Intelligence (AI) in Cancer Diagnostics Market in North America (2022-2032)
  • Table 15: Artificial Intelligence (AI) in Cancer Diagnostics Market in the United States (2022-2032)
  • Table 16: Artificial Intelligence (AI) in Cancer Diagnostics Market in Canada (2022-2032)
  • Table 17: Artificial Intelligence (AI) in Cancer Diagnostics Market in Mexico (2022-2032)
  • Table 18: Artificial Intelligence (AI) in Cancer Diagnostics Market in Europe (2022-2032)
  • Table 19: Artificial Intelligence (AI) in Cancer Diagnostics Market in France (2022-2032)
  • Table 20: Artificial Intelligence (AI) in Cancer Diagnostics Market in Germany (2022-2032)
  • Table 21: Artificial Intelligence (AI) in Cancer Diagnostics Market in United Kingdom (2022-2032)
  • Table 22: Artificial Intelligence (AI) in Cancer Diagnostics Market in Italy (2022-2032)
  • Table 23: Artificial Intelligence (AI) in Cancer Diagnostics Market in Spain (2022-2032)
  • Table 24: Artificial Intelligence (AI) in Cancer Diagnostics Market in the Rest of Europe (2022-2032)
  • Table 25: Artificial Intelligence (AI) in Cancer Diagnostics Market in Asia-Pacific (2022-2032)
  • Table 26: Artificial Intelligence (AI) in Cancer Diagnostics Market in China (2022-2032)
  • Table 27: Artificial Intelligence (AI) in Cancer Diagnostics Market in Japan (2022-2032)
  • Table 28: Artificial Intelligence (AI) in Cancer Diagnostics Market in India (2022-2032)
  • Table 29: Artificial Intelligence (AI) in Cancer Diagnostics Market in Australia (2022-2032)
  • Table 30: Artificial Intelligence (AI) in Cancer Diagnostics Market in South Korea (2022-2032)
  • Table 31: Artificial Intelligence (AI) in Cancer Diagnostics Market in Rest of Asia-Pacific (2022-2032)
  • Table 32: Artificial Intelligence (AI) in Cancer Diagnostics Market in the Rest of the World (2022-2032)
  • Table 33: Artificial Intelligence (AI) in Cancer Diagnostics Market in the Middle East (2022-2032)
  • Table 34: Artificial Intelligence (AI) in Cancer Diagnostics Market in Africa (2022-2032)
  • Table 35: Artificial Intelligence (AI) in Cancer Diagnostics Market in South America (2022-2032)
  • Table 36: Competitive Landscape
  • Table 37: Startup Funding & Investment Trends